secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0000950170-22-009922
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3
--------------------------------------------------------------------------------

- Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.
- ETX-810 Phase 2a in diabetic peripheral neuropathic pain failed primary endpoint; LSRP trial fully enrolled, topline data Q3 2022.
- ETX-155 Phase 1b photosensitive epilepsy interim results inconclusive due to lower exposure; Phase 2a MDD/PMD enrollment delayed pending root cause.
- Preclinical Kv7.2/3 channel opener on track for IND-enabling studies in 2022; early anxiolytic program for GAD continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/0000950170-22-009922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/elym-20220516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer